Ignite Creation Date:
2025-12-24 @ 9:56 PM
Ignite Modification Date:
2025-12-25 @ 7:34 PM
Study NCT ID:
NCT07252232
Status:
RECRUITING
Last Update Posted:
2025-12-24
First Post:
2025-11-13
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Sponsor:
Revolution Medicines, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-12-15
Start Date Type:
ACTUAL
Primary Completion Date:
2029-05-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-07-10
Completion Date Type:
ESTIMATED
First Submit Date:
2025-11-13
First Submit QC Date:
None
Study First Post Date:
2025-11-26
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-23
Last Update Post Date:
2025-12-24
Last Update Post Date Type:
ACTUAL